Developer docs
API playgroundTry for free, no card

Search company profiles

Aspen

Full company profile

uuid003dpfn

Namestring
Aspen
Legal namestring
Aspen Oss B.V.
Websiteurl
aspenapi.com
Company typeenum
Private
Founded yearint
1923
Descriptiontext

Aspen API is a Contract Development and Manufacturing Organization (CDMO) specializing in the development and commercial-scale production of complex Active Pharmaceutical Ingredients (APIs). The company operates as a business unit of Aspen Pharmacare Holdings Limited, a JSE-listed pharmaceutical conglomerate, with origins dating back to 1923 in the Netherlands (initially extracting animal pancreases for insulin) and a parallel South African lineage via Fine Chemicals Corporation (founded 1962, acquired by Aspen in 2004). Its manufacturing footprint spans four production sites — Oss (Netherlands, two facilities), Boxtel (Netherlands), Cape Town (South Africa via FCC), and Sioux City (USA) — supported by regional sales offices in Des Plaines (USA) and Tokyo (Japan).

The core product portfolio exceeds 60 established APIs organized into five technical sub-categories: High Potency & Oncology APIs manufactured under OEB 4/5 containment with OEL levels as low as 0.01 µg/m³; Peptides produced via proprietary GREEN CONTINUOUS LPPS alongside classical LPPS and SPPS methods; Narcotic & Analgesic APIs (UN INCB recognized) produced at FCC; Botanical Extraction APIs; and biochemical products such as Chorionic Gonadotrophin. The technology platform encompasses complex chemistries (ethynylation, Grignard, catalytic hydrogenation, bromination, hydride reductions) and advanced analytical capabilities (HRMS, LC-MS/MS, 500MHz NMR) running across 100+ stainless steel and glass-lined reactor vessels ranging from 100L to 10,000L.

Revenue is generated through two principal streams: project-based and long-term Contract Development and Manufacturing agreements (CDMO/CMO services spanning route selection, process development, scale-up, analytical validation, and commercial manufacturing) and commercial supply of established APIs to global pharmaceutical customers. The company sells exclusively on a B2B basis into three horizontally-segmented customer groups — multinational originator pharmaceutical companies, generic drug manufacturers, and innovative biotech startups — via a dedicated direct enterprise sales team supplemented by local distributors and regional offices. Pricing is contractually negotiated and not publicly disclosed, with revenue mechanics tied to project complexity, volume, and regulatory requirements.

Short descriptiontext

Aspen API is a pharmaceutical CDMO and API manufacturer operating as a business unit of Aspen Pharmacare, producing 60+ complex APIs including HPAPIs, peptides, narcotics, and botanicals across facilities in the Netherlands, South Africa, and USA for multinational, generic, and biotech pharmaceutical customers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
5,001–10,000
akta.pro rankint
HeadquartersDurban, South Africa
HQ citystring
Durban
HQ countrystring
South Africa
HQ regionstring
Africa
Markets served

Serves global market

Offices7 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
active pharmaceutical ingredients, contract manufacturing services, CDMO solutions, peptide synthesis, high potency APIs
Industry3 codes
PRIMARYHLAGABAA
Small-Molecule API & Intermediates CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAHAB
Small-Molecule API Commercial Manufacturing
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Pharmaceutical API Manufacturing
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Contract Development and Manufacturing (CDMO/CMO)
TypeProfessional Services
Description

Full-service API development and manufacturing for pharmaceutical companies. Services include process development, scale-up, analytical development, regulatory support, and commercial manufacturing. Revenue generated through project-based contracts and long-term manufacturing agreements with multinationals, generic manufacturers, and biotech companies.

aspenapi.com
2Established API Product Sales
TypeLicensing Royalties
Description

Sale of more than 60 established high-quality APIs including high potency, oncology, peptides, narcotics, analgesics, botanical extraction, and biochemical products. Revenue from product supply contracts to pharmaceutical customers globally.

aspenapi.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Aspen API is a Contract Development and Manufacturing Organization (CDMO) specializing in complex Active Pharmaceutical Ingredient (API) development and manufacturing. The company provides end-to-end services from process development and analytical development through commercial manufacturing, supported by more than 60 established high-quality APIs including high potency, oncology, peptides, narcotics, analgesics, botanical extraction, and biochemical products. Operations span four manufacturing facilities in the Netherlands, South Africa, and the United States, with regulatory approvals from US FDA, EMA, PMDA, EDQM, and other major health authorities.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Successfully passed multiple FDA inspections with no critical findings or Form 483 issued (7 successive US FDA inspections, last audit July 2018)
+2 more records
Product overview1 text field

Aspen API is a Contract Development and Manufacturing Organization (CDMO) specializing in complex Active Pharmaceutical Ingredients (APIs). The company operates as a single unified offering combining CDMO Solutions with an Established API Portfolio of more than 60 high-quality APIs. The core products span High Potency & Oncology APIs (HPAPIs with OEB 4/5 classifications), Peptides (manufactured via LPPS, SPPS, and proprietary GREEN CONTINUOUS LPPS technology), Narcotics & Analgesic APIs, Botanical Extraction APIs, and Chorionic Gonadotrophin. Supporting services include Analytical Development, Regulatory Support, and a broad Technology Platform enabling complex chemical reactions. The company operates facilities in the Netherlands (Oss, Boxtel), South Africa (Cape Town), and USA (Sioux City, Iowa), serving multinationals, generic manufacturers, and innovative biotech companies.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
1Fine Chemicals Corporation (FCC)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2013-01-01
Description

FCC is a wholly owned subsidiary of Aspen API located in Cape Town, South Africa. Specializes in narcotics, botanical extraction, and oncology APIs. Manufacturing approval from US FDA, PMDA, TGA, SAHPRA, EDQM/ANSM.

aspenapi.com
2Health Valley Netherlands
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaboration with the biggest Dutch Life Sciences & Health innovation network for staying informed about latest developments and innovation in the sector.

aspenapi.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Close contacts with educational institutes for innovation, knowledge sharing, and staying current with latest scientific developments.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Active and valued member directly involved in discussions within EMA, FDA, EDQM and ICH. Plays key role in expert panels and participates in USP and EP expert groups.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaboration on sustainable API production research and development projects.

6Studievereniging Jan Pieter Minckelers (TU Eindhoven)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Inspiring collaboration with study association for Chemical Engineering and Chemistry students. Aspen sponsors the association and shares knowledge through activities.

aspenapi.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

European CDMO specializing in complex APIs including HPAPIs, peptides, and highly potent compounds. Direct comparable to Aspen API's peptide manufacturing capabilities and HPAPI containment at OEB 4/5 levels with overlapping technology stacks in continuous flow and preparative chromatography.

TypeDirect peer
Description

India-headquartered CDMO with strong HPAPI and ADC payload manufacturing capabilities. Directly competes with Aspen API for high-potency oncology API contracts, with comparable OEB 4/5 containment infrastructure and global regulatory expertise (FDA, EMA, PMDA).

TypeDirect peer
Description

Swiss-headquartered global CDMO and the world's largest contract API manufacturer with deep HPAPI and peptide capabilities. Directly comparable to Aspen API across small-molecule APIs, HPAPI manufacturing, and complex chemistry problem-solving for the same multinational pharma and biotech customer base.

TypeDirect peer
Description

Swiss-listed contract manufacturer specializing exclusively in peptide APIs. Direct competitor to Aspen API's peptide business with overlapping customers in GLP-1 and peptide therapeutics supply chains, and similar GMP peptide manufacturing capabilities.

TypeDirect peer
Description

US-headquartered CDMO with strong small-molecule API development and manufacturing capabilities including HPAPIs and controlled substances. Direct competitor to Aspen API in the complex API CDMO segment, serving similar pharmaceutical customers across development and commercial stages.

TypeDirect peer
Description

Swiss API CDMO specializing in complex small-molecule APIs including controlled substances and steroids. Directly comparable to Aspen API's regulated API services, multi-site European manufacturing footprint, and focus on established commercial API products for originator and generic customers.

TypeDirect peer
Description

Indian-headquartered CDMO specializing in HPAPIs, oncology APIs, and complex chemistry. Direct comparable to Aspen API's cytotoxic API capabilities at Cape Town and peptide/HPA chemistry strengths, serving similar pharmaceutical customers.

TypeBroad incumbent
Description

Large US-headquartered CDMO with broad services spanning drug product, biologics, and APIs. While broader than Aspen API in scope, Catalent competes for similar development-stage and commercial API contracts and serves overlapping multinational pharma customers.

TypeDirect peer
Description

Global CDMO offering API development and manufacturing services including small-molecule APIs and complex chemistry. Directly competes with Aspen API for development-stage CDMO contracts and serves overlapping pharmaceutical and biotech customers.

10Jubilant Pharmova (Jubilant Life Sciences)
TypeDirect peer
Description

Indian integrated pharmaceutical company with CDMO services spanning small-molecule APIs and complex chemistry. Comparable to Aspen API's established API portfolio model and contract manufacturing scale, with similar global regulatory filing footprint.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance9 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Aspen

Pharmaceutical API Manufacturingaspenapi.com

Aspen API is a pharmaceutical CDMO and API manufacturer operating as a business unit of Aspen Pharmacare, producing 60+ complex APIs including HPAPIs, peptides, narcotics, and botanicals across facilities in the Netherlands, South Africa, and USA for multinational, generic, and biotech pharmaceutical customers.

What Aspen does

Aspen API is a Contract Development and Manufacturing Organization (CDMO) specializing in the development and commercial-scale production of complex Active Pharmaceutical Ingredients (APIs). The company operates as a business unit of Aspen Pharmacare Holdings Limited, a JSE-listed pharmaceutical conglomerate, with origins dating back to 1923 in the Netherlands (initially extracting animal pancreases for insulin) and a parallel South African lineage via Fine Chemicals Corporation (founded 1962, acquired by Aspen in 2004). Its manufacturing footprint spans four production sites — Oss (Netherlands, two facilities), Boxtel (Netherlands), Cape Town (South Africa via FCC), and Sioux City (USA) — supported by regional sales offices in Des Plaines (USA) and Tokyo (Japan).

The core product portfolio exceeds 60 established APIs organized into five technical sub-categories: High Potency & Oncology APIs manufactured under OEB 4/5 containment with OEL levels as low as 0.01 µg/m³; Peptides produced via proprietary GREEN CONTINUOUS LPPS alongside classical LPPS and SPPS methods; Narcotic & Analgesic APIs (UN INCB recognized) produced at FCC; Botanical Extraction APIs; and biochemical products such as Chorionic Gonadotrophin. The technology platform encompasses complex chemistries (ethynylation, Grignard, catalytic hydrogenation, bromination, hydride reductions) and advanced analytical capabilities (HRMS, LC-MS/MS, 500MHz NMR) running across 100+ stainless steel and glass-lined reactor vessels ranging from 100L to 10,000L.

Revenue is generated through two principal streams: project-based and long-term Contract Development and Manufacturing agreements (CDMO/CMO services spanning route selection, process development, scale-up, analytical validation, and commercial manufacturing) and commercial supply of established APIs to global pharmaceutical customers. The company sells exclusively on a B2B basis into three horizontally-segmented customer groups — multinational originator pharmaceutical companies, generic drug manufacturers, and innovative biotech startups — via a dedicated direct enterprise sales team supplemented by local distributors and regional offices. Pricing is contractually negotiated and not publicly disclosed, with revenue mechanics tied to project complexity, volume, and regulatory requirements.

Aspen firmographics

Firmographics
Name
Aspen
Legal name
Aspen Oss B.V.
Website
https://aspenapi.com
Company type
Private
Founded year
1923
Operating status
Operating
Headcount range
5,001–10,000 employees
Short description
Aspen API is a pharmaceutical CDMO and API manufacturer operating as a business unit of Aspen Pharmacare, producing 60+ complex APIs including HPAPIs, peptides, narcotics, and botanicals across facilities in the Netherlands, South Africa, and USA for multinational, generic, and biotech pharmaceutical customers.
Ownership category
akta.pro rank

Aspen industry classification

Industry
Product category
Pharmaceutical API Manufacturing
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGABAA
Small-Molecule API & Intermediates CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAHAB
Small-Molecule API Commercial Manufacturing
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Active pharmaceutical ingredients
  • Contract manufacturing services
  • CDMO solutions
  • Peptide synthesis
  • High potency APIs

Where Aspen is headquartered

Location

Headquarters

HQ city
Durban
HQ country
South Africa
HQ region
Africa

Offices7 records

Markets served

Aspen business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain

Revenue model

  1. Contract Development and Manufacturing (CDMO/CMO): Full-service API development and manufacturing for pharmaceutical companies. Services include process development, scale-up, analytical development, regulatory support, and commercial manufacturing. Revenue generated through project-based contracts and long-term manufacturing agreements with multinationals, generic manufacturers, and biotech companies.
  2. Established API Product Sales: Sale of more than 60 established high-quality APIs including high potency, oncology, peptides, narcotics, analgesics, botanical extraction, and biochemical products. Revenue from product supply contracts to pharmaceutical customers globally.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Aspen product offering

Product offering

Core offering

Aspen API is a Contract Development and Manufacturing Organization (CDMO) specializing in complex Active Pharmaceutical Ingredient (API) development and manufacturing. The company provides end-to-end services from process development and analytical development through commercial manufacturing, supported by more than 60 established high-quality APIs including high potency, oncology, peptides, narcotics, analgesics, botanical extraction, and biochemical products. Operations span four manufacturing facilities in the Netherlands, South Africa, and the United States, with regulatory approvals from US FDA, EMA, PMDA, EDQM, and other major health authorities.

Product overview

Aspen API is a Contract Development and Manufacturing Organization (CDMO) specializing in complex Active Pharmaceutical Ingredients (APIs). The company operates as a single unified offering combining CDMO Solutions with an Established API Portfolio of more than 60 high-quality APIs. The core products span High Potency & Oncology APIs (HPAPIs with OEB 4/5 classifications), Peptides (manufactured via LPPS, SPPS, and proprietary GREEN CONTINUOUS LPPS technology), Narcotics & Analgesic APIs, Botanical Extraction APIs, and Chorionic Gonadotrophin. Supporting services include Analytical Development, Regulatory Support, and a broad Technology Platform enabling complex chemical reactions. The company operates facilities in the Netherlands (Oss, Boxtel), South Africa (Cape Town), and USA (Sioux City, Iowa), serving multinationals, generic manufacturers, and innovative biotech companies.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

  • Successfully passed multiple FDA inspections with no critical findings or Form 483 issued (7 successive US FDA inspections, last audit July 2018)
  • +2 more outcomes

Companies that use Aspen

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Aspen technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Aspen partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and minor.

  • Fine Chemicals Corporation (FCC)coreStrategic or Co-development Partner · 1 January 2013FCC is a wholly owned subsidiary of Aspen API located in Cape Town, South Africa. Specializes in narcotics, botanical extraction, and oncology APIs. Manufacturing approval from US FDA, PMDA, TGA, SAHPRA, EDQM/ANSM.
  • Health Valley NetherlandsminorStrategic or Co-development PartnerCollaboration with the biggest Dutch Life Sciences & Health innovation network for staying informed about latest developments and innovation in the sector.
  • Educational Institutes (MSc and BSc)minorStrategic or Co-development PartnerClose contacts with educational institutes for innovation, knowledge sharing, and staying current with latest scientific developments.
  • APIC (Active Pharmaceutical Ingredients Committee)coreStrategic or Co-development PartnerActive and valued member directly involved in discussions within EMA, FDA, EDQM and ICH. Plays key role in expert panels and participates in USP and EP expert groups.
  • Wageningen Food and Biobased ResearchminorStrategic or Co-development PartnerCollaboration on sustainable API production research and development projects.
  • Studievereniging Jan Pieter Minckelers (TU Eindhoven)minorStrategic or Co-development PartnerInspiring collaboration with study association for Chemical Engineering and Chemistry students. Aspen sponsors the association and shares knowledge through activities.

Scale indicators6 records

Recent moves7 records

Expansion highlights5 records

Aspen competitors and assessment

Company assessment

Direct peers

  • Axplora (formerly Novasep): European CDMO specializing in complex APIs including HPAPIs, peptides, and highly potent compounds. Direct comparable to Aspen API's peptide manufacturing capabilities and HPAPI containment at OEB 4/5 levels with overlapping technology stacks in continuous flow and preparative chromatography.
  • Piramal Pharma Solutions: India-headquartered CDMO with strong HPAPI and ADC payload manufacturing capabilities. Directly competes with Aspen API for high-potency oncology API contracts, with comparable OEB 4/5 containment infrastructure and global regulatory expertise (FDA, EMA, PMDA).
  • Lonza: Swiss-headquartered global CDMO and the world's largest contract API manufacturer with deep HPAPI and peptide capabilities. Directly comparable to Aspen API across small-molecule APIs, HPAPI manufacturing, and complex chemistry problem-solving for the same multinational pharma and biotech customer base.
  • PolyPeptide Group: Swiss-listed contract manufacturer specializing exclusively in peptide APIs. Direct competitor to Aspen API's peptide business with overlapping customers in GLP-1 and peptide therapeutics supply chains, and similar GMP peptide manufacturing capabilities.
  • Cambrex: US-headquartered CDMO with strong small-molecule API development and manufacturing capabilities including HPAPIs and controlled substances. Direct competitor to Aspen API in the complex API CDMO segment, serving similar pharmaceutical customers across development and commercial stages.
  • Siegfried Holding: Swiss API CDMO specializing in complex small-molecule APIs including controlled substances and steroids. Directly comparable to Aspen API's regulated API services, multi-site European manufacturing footprint, and focus on established commercial API products for originator and generic customers.
  • Dishman Carbogen Amcis: Indian-headquartered CDMO specializing in HPAPIs, oncology APIs, and complex chemistry. Direct comparable to Aspen API's cytotoxic API capabilities at Cape Town and peptide/HPA chemistry strengths, serving similar pharmaceutical customers.
  • Curia (formerly AMRI): Global CDMO offering API development and manufacturing services including small-molecule APIs and complex chemistry. Directly competes with Aspen API for development-stage CDMO contracts and serves overlapping pharmaceutical and biotech customers.
  • Jubilant Pharmova (Jubilant Life Sciences): Indian integrated pharmaceutical company with CDMO services spanning small-molecule APIs and complex chemistry. Comparable to Aspen API's established API portfolio model and contract manufacturing scale, with similar global regulatory filing footprint.

Broad incumbents

  • Catalent: Large US-headquartered CDMO with broad services spanning drug product, biologics, and APIs. While broader than Aspen API in scope, Catalent competes for similar development-stage and commercial API contracts and serves overlapping multinational pharma customers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Aspen social profiles

Digital presence

Aspen compliance and trust

Trust signal

Compliance9 records

Aspen financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Aspen leadership team

Management profile

Number of profiles

Profiles7 records

Aspen subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Aspen funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Aspen M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aspen

What does Aspen do?

Aspen API is a Contract Development and Manufacturing Organization (CDMO) specializing in complex Active Pharmaceutical Ingredient (API) development and manufacturing. The company provides end-to-end services from process development and analytical development through commercial manufacturing, supported by more than 60 established high-quality APIs including high potency, oncology, peptides, narcotics, analgesics, botanical extraction, and biochemical products. Operations span four manufacturing facilities in the Netherlands, South Africa, and the United States, with regulatory approvals from US FDA, EMA, PMDA, EDQM, and other major health authorities.

Is Aspen a public or private company?

Aspen is a private company. It is classified as corporate owned and is currently operating.

When was Aspen founded?

Aspen was founded in 1923. It employs 5,001 to 10,000 people.

Where is Aspen based?

Aspen is headquartered in Durban, South Africa, in the Africa region.

How does Aspen make money?

Two revenue lines are on record. Contract Development and Manufacturing (CDMO/CMO) is the primary driver. The others are established API Product Sales.

Who are Aspen's main competitors?

Direct peers on record are Axplora (formerly Novasep), Piramal Pharma Solutions, Lonza, PolyPeptide Group, Cambrex, Siegfried Holding, Dishman Carbogen Amcis, Curia (formerly AMRI) and Jubilant Pharmova (Jubilant Life Sciences). Catalent is listed as a broad incumbent.

Does Aspen have an API?

No public API is recorded for Aspen.

What industry is Aspen in?

Aspen's product category is Pharmaceutical API Manufacturing. Its primary akta.pro industry code is HLAGABAA, Small-Molecule API & Intermediates CDMO, with a secondary code of HLAGAHAB, Small-Molecule API Commercial Manufacturing. Its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The GuardianHRT: inside the complex global supply chain behind a $20bn marketHRT production relies on a global supply chain from soya beans in China to British pharmacies, with Aspen API's Oss plant making oestradiol. UK shortages peaked at 700,000 prescriptions in May, and the market is valued at $20bn, expected to reach $36bn by 2030. Campaigners are urging a national formulary to ensure equal access.Daily NigerianCOVID-19: Why Africa is key to stopping next variant -- Report — Daily NigerianAfrica's first COVID-19 vaccine plant, Aspen in South Africa, is on the verge of closing due to lack of orders. Nigeria has vaccinated only 7.5% of its population, and scientists warn of an emerging fifth wave. The continent needs 1.095 billion more doses to reach 70% vaccination by 2024.Pivotpark100 Years Pharma FutureThe Oss pharma cluster in the Netherlands is launching a year-long series of events titled "100 Years Pharma Future," organised by Aspen, MSD, Organon and Pivot Park. The festivities begin in September 2022 and mark 100 years since Organon began large-scale medicine manufacturing, 25 years for MSD's biotech and 10 years for Pivot Park and Aspen.PR NewswireGlobal Active Pharmaceutical Ingredient (API) Market Report 2021-2025: Opportunities in Advancements in API Manufacturing, Growth in the CMOs, & Emergence of Biosimilars MarketResearchAndMarkets.com published a market report estimating the Global Active Pharmaceutical Ingredient market at USD 187.23 billion in 2020, projected to reach USD 255.56 billion by 2025 with a 6.42% CAGR. Key growth drivers include rising chronic disease incidence, increasing demand from developing nations, technological advancements in API synthesis, and the emergence of biosimilars, while price control policies and high manufacturing costs act as market restraints. Two recent industry developments are noted: Pfizer signed an agreement with Gilead Sciences in August 2020 to manufacture Remdesivir for COVID-19 treatment, and Novartis acquired Aspen's Japanese operations to strengthen its generics position.